CompletedNot Applicable

Bone Marrow Suppression and Recovery During Radionuclide Treatment

Denmark68 participantsStarted 2017-06-20

Plain-language summary

Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. More than 20 % of patients treated at Rigshospitalet develop bone marrow suppression as a side effect to Radium therapy The aim of the study is to examine biomarkers of bone marrow suppression and recovery during Radium therapy as well as markers of bone remodeling.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Metastatic castration resistant prostate cancer * Planned to initiate Radium therapy * Age \> 18 years * Able to understand study protocol and give informed consent Exclusion Criteria: * None

What they're measuring

Thrombocytopenia

Timeframe: Within 1 year from inclusion

Timeframe: within 1 year from inclusion

Bone markers

Timeframe: Within 12 months from inclusion

Trial details

NCT IDNCT03247010

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-10-01

View on ClinicalTrials.gov More Castration-resistant Prostate Cancer trials